Healthy, Pharmacokinetics of ASP1941
Conditions
Keywords
ASP1941, Actos, pioglitazone hydrochloride
Brief summary
The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and pioglitazone hydrochloride in multiple and single doses.
Detailed description
All subjects will be enrolled at one center and confined to the unit for up to 23 days. Subjects will be dosed in the fasting state in one of the four groups.
Interventions
DRUGASP1941
oral tablet
oral tablet
Sponsors
Astellas Pharma Inc
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* The subject weighs at least 50 kg, and has a body mass index (BMI) of 18 to 32 kg/m2 inclusive * The subject's 12-lead electrocardiogram (ECG) results are normal * The female subject must be at least two years postmenopausal, surgically sterile or practicing effective birth control and not pregnant or lactating * The male or female subject agrees to practice highly effective birth control from Screening until 7 days post last dose
Exclusion criteria
* The subject has a history or evidence of any clinically significant (as determined by the investigator) cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy (excluding non-melanoma skin cancer) * The subject has any condition possibly affecting drug absorption (e.g., gastrectomy) * The subject has history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening or the subject tests positive for alcohol or drugs of abuse * The subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check in * The subject has a supine mean systolic blood pressure \< 90 or \> 160 mmHg and a mean diastolic blood pressure \< 50 or \> 90 mmHg, or pulse rate higher than 100 beats per min (bpm) * The subject has a 12-lead ECG demonstrating QTc \>470 msec (female) or \>450 msec (male) * The subject is known positive for human immunodeficiency virus (HIV) antibody * The subject has a positive test for tuberculosis (TB), hepatitis C antibody, or positive for hepatitis B antigen (HBsAg) * The subject has used prescription or non-prescription drugs within 2 weeks or 5 half-lives (whichever is longer) or complementary and alternative medicines (CAM) within 14 days prior to study drug administration (excluding oral contraceptives, hormone replacement therapy \[HRT\], and acetaminophen) * The subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic variables assessment through analysis of blood samples | Day 1 and up to Day 21 |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacodynamic variables assessment through analysis of blood and urine samples | Day -1 and up to Day 17 |
| Safety assessed by recording of adverse events, laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations | Day 1 through scheduled group check out (Day 13 and up to Day 21) or early termination |
Countries
United States
Outcome results
None listed